SK Bioscience reported that it conducted ‘vaccine production process’ training for trainees at the WHO human resources training hub at ‘Andong L House’ located in Andong, Gyeongsangbuk-do. This educational program, jointly promoted by the Ministry of Health and Welfare, the Ministry of Strategy and Finance, Yonsei University’s K-NIBRT Project Group, and the Asian Development Bank (ADB), is designed to foster vaccine production talent in middle and low-income countries in accordance with WHO’s exclusive designation of Korea as a ‘global bio human resources training hub’. This was carried out to resolve regional gaps in vaccine production capacity.
In fact, the gap in infectious disease response capabilities between countries and regions has been identified as a major cause of the prolonged COVID-19 pandemic. Accordingly, countries around the world, including the government of the Republic of Korea, are continuing various collaborations to strengthen their capabilities to respond to future infectious diseases. In this situation, Korea was designated as a ‘Global Bio Human Resources Development Hub’, an education and training institution for vaccine and biopharmaceutical production processes, by WHO in February based on the vaccine and biotechnology production capabilities of domestic companies and excellent education infrastructure.
On this day’s training, 26 trainees from 12 developing countries in the Asian Development Bank (ABD) region, including Vietnam, Indonesia, and Thailand, took a first-hand look at the production facility where Korea’s first COVID-19 vaccine ‘Skycovid One Multi-Injection’ was created. I took my time. Trainees experienced Korea’s excellent vaccine production process by directly touring the vaccine concentrate and finished product production facilities and quality control laboratory at ‘Andong L House’.
In particular, Andong L House was the first domestic vaccine manufacturing facility to obtain EU-GMP (Good Manufacturing Practice) certification approved by the European Medicines Agency (EMA), and in addition, regulatory agencies including WHO ( It has been recognized for its global level production capabilities by obtaining GMP from the Turkish Pharmaceutical and Medical Devices Agency, the British Medicines Regulatory Agency, and the Russian Ministry of Health.
Mozahidur Rahaman from Bangladesh, who participated in the training, said, “It was a valuable time to see and feel with my own eyes a world-class production facility that produces various types of vaccines that I had only experienced in theory.” , “Based on today’s experience, I was inspired to grow to be able to keep more people safe in the future when new viruses emerge.”
Jaeyong Ahn, President of SK Bioscience, said, “Nurturing global bio talent is the responsibility of those in the vaccine field and the most basic effort to protect humanity from new pandemics.” He added, “Starting with this training, we will support the growth of bio talent at home and abroad in both material and spiritual ways.” “He said.
Meanwhile, SK Bioscience is continuing its efforts to lead the domestic and overseas bio industry and cultivate human resources. Last October, we provided scholarships to four domestic universities to foster local talent, and signed a memorandum of understanding (MOU) with the Hillemann Institute, which has world-class R&D technology, including mutual cooperation in human resource development. In addition, the ‘Global R&PD (Research and Process Development) Center’, scheduled to be completed in the Incheon Free Economic Zone in 2025, will serve as a human resources training hub in connection with international organizations, domestic and foreign bio companies and research institutes.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news